| Literature DB >> 29072634 |
Ah Reum Kim1, Juyong Chung2, Nayoung K D Kim3, Chung Lee4, Woong-Yang Park5,6, Doo-Yi Oh7, Byung Yoon Choi8,9.
Abstract
We performed targeted re-sequencing to identify the genetic etiology of early-onset postlingual deafness and encountered a frequent TMPRSS3 allele harboring two variants in a cis configuration. We aimed to evaluate the pathogenicity of the allele. Among 88 cochlear implantees with autosomal recessive non-syndromic hearing loss, subjects with GJB2 and SLC26A4 mutations were excluded. Thirty-one probands manifesting early-onset postlingual deafness were sorted. Through targeted re-sequencing, we detected two families with a TMPRSS3 mutant allele containing p.V116M and p.V291L in a cis configuration, p.[p.V116M; p.V291L]. A minor allele frequency was calculated and proteolytic activity was measured. A p.[p.V116M; p.V291L] allele demonstrated a significantly higher frequency compared to normal controls and merited attention due to its high frequency (4.84%, 3/62). The first family showed a novel deleterious splice site variant-c.783-1G>A-in a trans allele, while the other showed homozygosity. The progression to deafness was noted within the first decade, suggesting DFNB10. The proteolytic activity was significantly reduced, confirming the severe pathogenicity. This frequent mutant allele significantly contributes to early-onset postlingual deafness in Koreans. For clinical implication and proper auditory rehabilitation, it is important to pay attention to this allele with a severe pathogenic potential.Entities:
Keywords: DFNB8/10; TMPRSS3 mutation; cochlear implantation; deafness; sensorineural hearing loss
Mesh:
Substances:
Year: 2017 PMID: 29072634 PMCID: PMC5713216 DOI: 10.3390/ijms18112246
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Pedigrees of the two families related to TMPRSS3 and audiograms of affected subjects. (a) In this pedigree, the most likely haplotype of TMPRSS3 is reconstructed based on the segregation study. The p.[p.V116M; p.V291L] allele (grey box) is shared by the two unrelated probands (red arrow). (b) Pure tone audiometry obtained from both probands directly before cochlear implantation is presented. Severe-to-profound hearing loss with minimal residual hearing is shown. Red colored graph refers to left-sided hearing loss and blue colored graph refers to right-sided hearing loss.
List of the variants surviving from initial filtering based on the TRS200, TRS129 analysis. Details of final candidates after targeted re-sequencing of the 200, 129 deafness genes, respectively.
| Gene | Exon | Nucleotide Change | Amino Acid Change | Pathogenicity Prediction | Zygosity | |
|---|---|---|---|---|---|---|
| SIFT | ||||||
| SNUH67-156 | exon85 | c.G11602A | p.V3868M | Tolerated | Hetero | |
| exon1 | c.T140C | p.L47P | Tolerated | Hetero | ||
| exon4 | c.391_393delAAG | p.K131del | NA | Hetero | ||
| exon9 | c.A1567G | p.M523V | Tolerated | Hetero | ||
| exon33 | c.A4772G | p.Q1591R | Tolerated | Hetero | ||
| exon1 | c.215_223delATCACCACC | p.H72_H74del | NA | Hetero | ||
| exon3 | c.G1823A | p.R608H | Tolerated | Hetero | ||
| exon2 | c.486_487insGGC | p.P163delinsGP | NA | Hetero | ||
| exon9 | c.G871C | p.V291L | NA | Hetero | ||
| intron9 | c.783-1G>A | NA | NA | Hetero | ||
| exon5 | c.G346A | p.V116M | NA | Hetero | ||
| exon7 | c.1613_1615delTGT | p.L538_S539delinsP | NA | Hetero | ||
| SNUH174-387 | exon30 | c.G1741A | p.V581I | Tolerated | Hetero | |
| exon3 | c.G193A | p.G65R | Tolerated | Hetero | ||
| exon5 | c.G688T | p.G230W | Damaging | Hetero | ||
| exon1 | c.C761T | p.S254L | Tolerated | Hetero | ||
| exon40 | c.G5411A | p.R1804Q | Tolerated | Hetero | ||
| exon16 | c.G1927A | p.G643S | Tolerated | Hetero | ||
| exon28 | c.G2785A | p.D929N | Tolerated | Hetero | ||
| exon9 | c.G871C | p.V291L | NA | Homo | ||
| exon5 | c.G346A | p.V116M | NA | Homo |
* Causal variants based on the autosomal recessive inheritance pattern in two probands, respectively.
Overview of the three variants in TMPRSS3.
| Exon/Intron | Nucleotide Change | Amino Acid Change | Domain | Minor Allele Frequency | Phenotype | References | |||
|---|---|---|---|---|---|---|---|---|---|
| UCSC | 1000G | KRGDB | SGI | ||||||
| Exon5 | c.G346A | p.V116M | SRCR | 0.0015 | 0 | 0 | 0 | † Profound | [ |
| Intron8 | c.783-1G>A | - | - | 0 | 0 | 0 | 0 | Likely pathogenic | This Study |
| Exon9 | c.G871C | p.V291L | Serine Protease | 0.00005 | 0.0006 | 0.0008 | 0 | Uncertain | [ |
UCSC (University of California, Santa Cruz) genome browser, GRCh37 hg19: a database of genomic sequence and annotation data for a wide variety of organisms; 1000G (Genomes Project data): extensive genome annotation, such as protein-coding genes and whole-genome regulatory information though the dedicated 1000 Genomes browser; KRGDB: Total 622 individuals from the Korean Reference Genome Database; SGI (Samsung genomic institute) in house database Korean 1000; †Profound, Childhood onset (10–12 years) affecting all frequencies or prelingual profound deafness.
Figure 2Sanger sequencing traces, conservation, and residing domains of TMPRSS3 variants in this study. (a) Sanger sequencing chromatograms show p. V116M, p.V291L, and c.783-1G>A variants in a heterozygous fashion from SNUH67-156. (b) The variants, p. V116M and p.V291L, are in a homozygous fashion from SNUH174-387. (c) Conservation status of the two missense variants among various species from human to zebrafish. (d) Two missense variants in its domain of TMPRSS3; The residue of p.V116 and p.V291is located in the SRCR and the serine protease domain, respectively.
Figure 3Assay for the proteolytic activity of the transformants of each genotype of TMPRSS3. Colonies were counted with the criteria in a well-shaped order. Far left panel indicates the wild type controls; right indicates null function controls. Compared with these, the middle one contains the proteolytic activity of double mutated constructs: the double mutants, p.V116M and p.V291L, show a significantly weaker proteolytic activity than the one on the left, suggesting pathogenicity. (A medium containing Leu−/Trp− + 2% Sucrose + Cu2+ + 0.5 mg/mL Antimycin).